Ketamine

Syringe labelled 'ketamine'

A case study on ketamine reveals systemic barriers that prevent repurposing existing low-cost drugs like ketamine for treatment-resistant depression.

A phial of ketamine

Promising results in a trial of ketamine for severe depression could lead to treatment becoming more affordable.

Person surrounded by hands with psychedelic colours and patterns

Australia needs to be careful when implementing MDMA and psilocybin therapy, says UNSW researcher Professor Colleen Loo.

loo.jpg

Researchers from the Black Dog Institute and UNSW Sydney have questioned the efficacy and safety of intranasal ketamine for depression, with their pilot trial stopped early due to poor side effects in patients.

9_colleen_loo_2_2.jpg

Researchers from UNSW and Black Dog Institute say major gaps in the literature must be addressed before ketamine is widely adopted as a clinical treatment for depression.

24_ketamine_shutterstock.jpg

UNSW researchers at Black Dog Institute have preliminary evidence that suggests ketamine is effective as an antidepressant when delivered to elderly patients in repeated intravenous doses.  

9_colleen_loo.jpg

The largest randomised control trial to evaluate the effectiveness of ketamine as a new treatment for major depression has begun across Australia and New Zealand.

9_colleen_loo.jpg

We should resist pressure to prescribe ketamine to treat depression until clinical trials on the drug's long-term safety and effectiveness are completed, a leading UNSW mental health expert says.

9_colleen_loo.jpg

A $2.1 million grant from the National Health and Medical Research Council announced today will see UNSW Professor Colleen Loo lead Australia’s largest clinical trial of ketamine as a new treatment for major depression.

11 colleen loo 0 0

A drug traditionally used as an anaesthetic and sometimes used recreationally could be effective in preventing suicide in severely depressed patients, says a UNSW academic who has trialled the drug.

Pages